Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Nurix Therapeutics, Inc. (NRIX) is a Biotechnology company based in US with a market capitalization of $1.5B. Revenue grew 54.0% year-over-year and free cash flow was negative at -$263.5M. This page tracks NRIX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 286 employees · IPO Jul 24, 2020

Valuation

Valuation & price

$15.86as of May 17, 2026· -34.6% vs 52w high

P/E ratio

Latest-FY diluted EPS

2.87

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$23.97$16.20$8.43Jul 25Dec 25Jul 26
$8.2452-week range$24.26
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

54.0%

Revenue growth (YoY)

77.5%

Gross margin

-$263.5M

Free cash flow (USD)

-$537.2M

Net debt

Net cash position

29.1%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20182025

$37.4M$84M

Free cash flow by year

20182025

-$33.3M-$263.5M

Gross margin by year

20212025

-291.4%77.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

10

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellJul 2, 2026Filing

    Insider Sell $259K · 10b5-1 PlanRing Christine · Chief Legal Officer · $259.4K

  • Insider sellJun 25, 2026Filing

    Insider Sell $108K · 10b5-1 PlanHansen Gwenn · Chief Scientific Officer · $107.9K

  • Insider sellJun 25, 2026Filing

    Insider Sell $581K · 10b5-1 PlanRing Christine · Chief Legal Officer · $580.5K

  • 8-K eventJun 11, 2026Filing

    Clinical Data Update

  • 8-K eventJun 8, 2026Filing

    Collaboration Agreement

  • Insider sellJun 2, 2026Filing

    Insider Sell $135K · 10b5-1 PlanRing Christine · Chief Legal Officer · $135.3K

  • 8-K eventMay 15, 2026Filing

    Annual Meeting Results

  • Insider sellMay 5, 2026Filing

    Insider Sell $233K · 10b5-1 Planvan Houte Hans · Chief Financial Officer · $233.3K

  • Insider sellMay 4, 2026Filing

    Insider Sell $138K · 10b5-1 PlanRing Christine · Chief Legal Officer · $138.2K

  • Insider sellMay 1, 2026Filing

    Insider Sell $90K · 10b5-1 PlanRing Christine · Chief Legal Officer · $90.4K

Questions

Frequently asked questions

What is Nurix Therapeutics, Inc.'s market cap?

Nurix Therapeutics, Inc. (NRIX) has a market capitalization of $1.5B.

What is NRIX's P/E ratio?

A meaningful P/E ratio is not available for NRIX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NRIX's price-to-book (P/B) ratio?

NRIX trades at 2.87 times book value per share.

Are insiders buying NRIX stock?

SEC Form 4 filings show no open-market insider buys at Nurix Therapeutics, Inc. in the last 90 days (10 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.